[Gynecological, hematological and metabolic studies during therapy with an estrogen-gestagen combination preparation].
Twenty women after menopause were submitted to substitution treatment with a biphasic hormone combination (Cyclacur¿). Nine of these had undergone hysterectomy + ovarectomy. Through 11 days each of the women was administered a daily dose of 2 mg estradiol-valerianate as estrogen. Subsequently, for another 10 days each was given the identical dose of estrogen plus 0.5 mg DL-norgestrel as gestagen. Upon this followed an intermission of 7 days without any medication. After 1 cycle of placebo, 7 cycles of medication were followed by 1 cycle of placebo again with regular controls. Climacteric signs and symptoms were eliminated entirely. In those women without hysterectomy withdrawal-menorrhagia occurred promptly 2--3 days after discontinuing medication. During the entire period of investigation there was no significant change in serum lipids, blood sugar values, or serum enzyme tests used as parameter of hepatic function. As far as hematology is concerned there was a moderate rise of hematocrit. No change of serum protein-bound iodine was observed.
D000410:Alanine Transaminase / Q000097:blood; D000469:Alkaline Phosphatase / Q000097:blood; D001219:Aspartate Aminotransferases / Q000097:blood; D001772:Blood Cell Count; D001786:Blood Glucose / Q000032:analysis; D001794:Blood Pressure / Q000187:drug effects; D002584:Cervix Uteri / Q000187:drug effects; D002979:Climacteric / Q000187:drug effects; D002986:Clinical Trials as Topic; D003276:Contraceptives, Oral / Q000494:pharmacology*; D003279:Contraceptives, Oral, Sequential / Q000494:pharmacology*; D004958:Estradiol / Q000494:pharmacology*; D005260:Female; D006400:Hematocrit; D006801:Humans; D008593:Menopause / Q000187:drug effects; D008875:Middle Aged; D009644:Norgestrel / Q000494:pharmacology*; D010919:Placebos; D014280:Triglycerides / Q000097:blood; D014621:Vagina / Q000187:drug effects; D014626:Vaginal Smears
D001786:Blood Glucose; D003276:Contraceptives, Oral; D003279:Contraceptives, Oral, Sequential; D010919:Placebos; D014280:Triglycerides; D009644:Norgestrel; D004958:Estradiol; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D000469:Alkaline Phosphatase
Gynäkologische, hämatologische und Stoffwechseluntersuchungen unter der Therapie mit einem Ostrogen-Gestagen-Kombinationspräparat